MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
October 30 2023 - 6:15AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products and devices for patients with endocrine and
orphan lung diseases, today announced a new patent (No. 11,793,808)
issued by the United States Patent and Trademark Office covering
clofazimine inhalation suspension (MNKD-101), which is under
development for the potential treatment of nontuberculous
mycobacterial (NTM) lung disease. The patent will expire on June 8,
2039.
“We believe this patent represents important
protection for our lead pipeline asset, MNKD-101, that could
potentially improve therapy for a disease that is increasingly on
the rise globally,” said Michael Castagna, PharmD, Chief Executive
Officer for MannKind Corporation. “Patients living with NTM
typically rely on a series of drug treatments that often may be
associated with severe side effects. Early data for MNKD-101 is
promising as it suggests rapid and targeted delivery of clofazimine
deep into the lung has the potential to be better tolerated.”
Pulmonary NTM infection is recognized as a major
global health concern due to its rising prevalence worldwide. It is
a serious infection that is caused by bacteria common in the
environment that can lead to a reduction in lung function, cough,
fatigue, and quality of life. It is estimated that approximately
86,000-180,000 people in the U.S. alone are living with NTM lung
disease, and it is on the rise growing 8% each year with women, the
elderly, and those with underlying lung conditions at greatest
risk. MNKD-101 has been designated by the FDA as both an orphan
drug and a qualified infectious disease product (QIDP) for the
treatment of pulmonary NTM infections.
About MannKindMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
innovative therapeutic products and devices to address serious
unmet medical needs for those living with endocrine and orphan lung
diseases.
We are committed to using our formulation
capabilities and device engineering prowess to lessen the burden of
diseases such as diabetes, pulmonary arterial hypertension (PAH)
and nontuberculous mycobacterial (NTM) lung disease. Our
signature technologies – dry-powder formulations and inhalation
devices – offer rapid and convenient delivery of medicines to the
deep lung where they can exert an effect locally or enter the
systemic circulation.
With a passionate team of Mannitarians
collaborating nationwide, we are on a mission to give people
control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and
follow us on LinkedIn, Facebook, Twitter or Instagram.
Forward-Looking StatementsThis
press release contains forward-looking statements about the
implications of clinical data and the potential safety of an
investigational product that involve risks and uncertainties. Words
such as “believes”, “anticipates”, “plans”, “expects”, “intends”,
“will”, “goal”, “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon MannKind’s current expectations. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the risk that continued testing of an investigational drug product
may not yield successful results or results that are consistent
with earlier testing, and other risks detailed in MannKind’s
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for the year ended December 31, 2022 and
subsequent periodic reports on Form 10-Q and current reports on
Form 8-K. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. All forward-looking statements are qualified in
their entirety by this cautionary statement, and MannKind
undertakes no obligation to revise or update any forward-looking
statements to reflect events or circumstances after the date of
this press release.
MNKD-101 is an investigational product that is not
approved for any use in any country.
MANNKIND is a registered trademark of MannKind
Corporation.
For MannKind:
Christie Iacangelo, Corporate Communications
(818) 292-3500
Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024